We specialise in diagnostic and therapeutic techniques for treatment resistant depression in children and adults.

Current biomedical and psychological models of depression typically identify and treat depression symptomatically without considering the underlying neurobiology (APA, 1994; Beck, 2005; Kupfer et al., 2002) . A significant number of these patients do not respond to traditional treatments for depression or show very poor treatment response.

The underlying neurobiological and psychological causes of depression can be extremely diverse with both organic and psychological/developmental conditions contributing to the depressive symptoms (Albert et al., 2004; Brodaty et al., 2005; 2001; Dieguez et al., 2004; Fujikawa et al., 1997; Jensen et al., 1996; Kemp et al., 2005; Nickel et al., 2007; Perrella et al., 2006; Shea et al., 1992; van Pragg, 1998; Villeneuve & Lemelin, 2005; Waldstein et al., 2003).

Our whole brain function and psychological testing in conjunction with a clinical interview can help to clarify your mood disorder to aid in the identification of more affective treatment and intervention using both pharmacological (medication) and psychological (psychotherapy) methods.

Once your condition is clarified a number of new psychological and pharmacological treatments are now available for treatment resistant depression (Alexopoulos, 2001; Bellino et al., 2006; El-Mallakh, 2000; Grade et al., 1998; Hammond, 2005; Johnson et al., 1992; McMain & Pos, 2007; Meares, 1980; 2006; Meares & Sara, 1995; Nasr, 2004; Nickel et al., 2007; Perrella et al., 2006; Purper-Ouakil et al., 2005; Rozelle & Budzynski, 1995; Sattar et al., 2002; Schwartz et al., 2004; Sookman & Steketee, 2007; Spencer et al., 2006; Stevenson et al., 2005; Vaishnavi et al., 2006; Villeneuve & Lemelin, 2005; Xiong et al., 2005).

In addition to cognitive behavioural therapy, depending on your presentation and profile this will generally include another therapeutic form such as neurofeedback, psychodynamic, self-psychology approaches and specialised schema based therapies have been shown to have positive results (Hammond, 2005; McMain & Pos, 2007; Meares, 2006; Rozelle & Budzynski, 1995; Silver et al., 1995; Sookman & Steketee, 2007; Spinhoven et al., 2007; Stevenson et al., 2005).

	Read and find out more about our treatment options.
	Read about our personalized medicine approach for depression.
	Read some of our case examples on depression.
	Look at some of our scientific publications on brain injury.

References

Albert, U, Maina, G, Forner, F, and Bogetto, F (2004). DSM-IV obsessive-compulsive personality disorder: Prevalence in patients with anxiety disorders and in healthy comparison subjects. Comprehensive Psychiatry , 45 (5), 325-332.

Alexopoulos, GS (2001). New Concepts for Prevention and Treatment of Late-Life Depression. American Journal of Psychiatry , 158 (6), 835-838.

APA (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th. American Psychiatric Association, Washington, DC.

Beck, AT (2005). The Current State of Cognitive Therapy: A 40-Year Retrospective. Archives of General Psychiatry , 62 (9), 953-959.

Bellino, S, Paradiso, E, and Bogetto, F (2006). Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. Journal of Clinical Psychiatry , 67 (7), 1042-1046.

Brodaty, H, Sachdev, P, Withall, A, Altendorf, A, Valenzuela, MJ, and Lorentz, L (2005). Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke - the Sydney Stroke Study. Psychological Medicine , 35 (12), 1707-1716.

Brodaty, H, Luscombe, G, Parker, G, Wilhelm, K, Hickie, I, AUSTIN, MP, and Mitchell, P (2001). Early and late onset depression in old age: different aetiologies, same phenomenology. Journal of Affective Disorders , 66 (2-3), 225-236.

Dieguez, S, Staub, F, Bruggimann, L, and Bogousslavsky, J (2004). Is poststroke depression a vascular depression? Journal of the Neurological Sciences , 226 (1-2), 53-58.

El-Mallakh, RS (2000). An open study of methylphenidate in bipolar depression. Bipolar Disorders , 2 (1), 56-59.

Fujikawa, T, Yanai, I, and Yamawaki, S (1997). Psychosocial Stressors in Patients With Major Depression and Silent Cerebral Infarction. Stroke , 28 (6), 1123-1125.

Grade, C, Redford, B, Chrostowski, J, Toussaint, L, and Blackwell, B (1998). Methylphenidate in early poststroke recovery: A double-blind, placebo-controlled study. Archives of Physical Medicine and Rehabilitation , 79 (9), 1047-1050.

Hammond, DC (2005). Neurofeedback with anxiety and affective disorders. Child & Adolescent Psychiatric Clinics of North America , 14 (1), 105-123, vii.

Jensen, PS, Hoagwood, K, and Petti, T (1996). Outcomes of mental health care for children and adolescents: II. Literature review and application of a comprehensive model. Journal of the American Academy of Child and Adolescent Psychiatry , 35 ( 1064-1077.

Johnson, ML, Roberts, MD, Ross, AR, and Witten, CM (1992). Methylphenidate in stroke patients with depression. American Journal of Physical Medicine & Rehabilitation , 71 (4), 239-241.

Kemp, AH, Stephan, BC, Hopkinson, P, Sumich, AL, Paul, RH, Clark, CR, Gordon, E, Bryant, RA, and Williams, LM (2005). Toward an integrated profile of depression: evidence from the brain resource international database. Journal of Integrative Neuroscience , 4 (1), 95-106.

Kupfer, DJ, First, MB, and Regier, DA (2002). A research agenda for DSM-V. American Psychiatric Association, Washington, D.C..

McMain, S and Pos, AE (2007). Advances in psychotherapy of personality disorders: a research update. Current Psychiatry Reports , 9 (1), 46-52.

Meares, R (1980). A psychodynamic view of anxiety. Handbook of Studies on Anxieyt , x ( 39-57.

Meares, R (2006). Re: Recent advances in the treatment of borderline personality disorder. Canadian Journal of Psychiatry , 51 (5), 333-334.

Meares, R and Sara, G (1995). Outcome Studies of Psychotherapy in Borderline Personality Disorder. Directions in Psychiatry , 15 ( 1-7.

Nasr, S (2004). Modafinil as adjunctive therapy in depressed outpatients. Annals of Clinical Psychiatry , 16 (3), 133-138.

Nickel, MK, Loew, TH, and Gil, FP (2007). Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology (Berl) , 191 (4), 1023-1026.

Perrella, C, Carrus, D, Costa, E, and Schifano, F (2006). Quetiapine for the treatment of borderline personality disorder; an open-label study. Progress in Neuro-psychopharmacology and Biological Psychiatry , In Press, Corrected Proof (.

Purper-Ouakil, D, Fourneret, P, Wohl, M, and Reneric, JP (2005). Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Encephale , 31 (3), 337-348.

Rozelle, GR and Budzynski, TH (1995). Neurotherapy for stroke rehabilitation: a single case study. Biofeedback & Self Regulation , 20 (3), 211-228.

Sattar, SP, Ucci, B, Grant, K, Bhatia, SC, and Petty, F (2002). Quetiapine therapy for posttraumatic stress disorder. The Annals of Pharmacotherapy , 36 (12), 1875-1878.

Schwartz, TL, Azhar, N, Cole, K, Hopkins, G, Nihalani, N, Simionescu, M, Husain, J, and Jones, N (2004). An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Journal of Clinical Psychiatry , 65 (9), 1223-1227.

Shea, MT, Widger, TA, and Klein, MH (1992). Comorbidity of personality disorders and depression: Implications for treatment. Journal of Consulting and Clinical Psychology , 60 ( 857-869.

Silver, SM, Brooks, A, and Obenchain, J (1995). Treatment of Vietnam War veterans with PTSD: a comparison of eye movement desensitization and reprocessing, biofeedback, and relaxation training. Journal of Trauma and Stress , 8 (2), 337-342.

Sookman, D and Steketee, G (2007). Directions in Specialized Cognitive Behavior Therapy for Resistant Obsessive-Compulsive Disorder: Theory and Practice of Two Approaches. Cognitive and Behavioral Practice , 14 (1), 1-17.

Spencer, TJ, Faraone, SV, Michelson, D, Adler, LA, Reimherr, FW, Glatt, SJ, and Biederman, J (2006). Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. Journal of Clinical Psychiatry , 67 (3), 415-420.

Spinhoven, P, Giesen-Bloo, J, van, DR, Kooiman, K, and Arntz, A (2007). The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. Journal of Consulting and Clinical Psychology , 75 (1), 104-115.

Stevenson, J, Meares, R, and D'Angelo, R (2005). Five-year outcome of outpatient psychotherapy with borderline patients. Psychological Medicine , 35 (1), 79-87.

Vaishnavi, SM, Gadde, KM, Alamy, SM, Zhang, WM, Connor, KM, and Davidson, JRT (2006). Modafinil for Atypical Depression: Effects of Open-label and Double-blind Discontinuation Treatment. Journal of Clinical Psychopharmacology , 26 (4), 373-378.

van Pragg, HM (1998). The diagnosis of depression in disorder. Australian and New Zealand Journal of Psychiatry , 32 ( 767-772.

Villeneuve, E and Lemelin, S (2005). Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: Impulsivity as main target. Journal of Clinical Psychiatry , 66 (10), 1298-1303.

Waldstein, SR, Tankard, CF, Maier, KJ, Pelletier, JR, Snow, J, Gardner, AW, Macko, R, and Katzel, LI (2003). Peripheral Arterial Disease and Cognitive Function. Psychosomatic Medicine , 65 (5), 757-763.